Treatment of Anxiety Disorders with SSRIs and SNRIs

Introduction to SSRIs and SNRIs

The American Academy of Child and Adolescent Psychiatry recommends SSRIs as the initial treatment choice for most patients with anxiety disorders, due to their established efficacy and safety profile 1, 3
SSRIs demonstrate high treatment response rates with a Number Needed to Treat (NNT) of 4.70 for anxiety disorders, indicating a strong therapeutic effect 1, 2
SNRIs show similar efficacy with an NNT of 4.94, comparable to SSRIs, suggesting that both medication classes can be effective for anxiety disorders 1, 2

Both medication classes produce significant improvements in anxiety symptoms compared to placebo, with similar dropout rates to placebo, indicating that they are both effective and generally well-tolerated 2, 4
The American Academy of Child and Adolescent Psychiatry suggests that SSRIs may have discontinuation syndromes, particularly with shorter-acting agents like paroxetine, fluvoxamine, and sertraline, highlighting the need for careful consideration when selecting an SSRI 7
Some SSRIs like citalopram/escitalopram may have fewer drug interactions due to less effect on CYP450 isoenzymes, making them a potentially safer choice for patients with complex medication regimens 7

The American Academy of Child and Adolescent Psychiatry recommends considering patient-specific factors such as comorbidities, previous response, and potential drug interactions when selecting an SSRI or SNRI 7
Escitalopram and sertraline are often preferred first-line SSRIs based on efficacy and tolerability profiles, suggesting that they may be good initial choices for many patients 2, 4
Venlafaxine has the most evidence among SNRIs for anxiety disorders, indicating that it may be a good alternative for patients who do not respond to SSRIs 1, 2

Patients should be informed that therapeutic effects of SSRIs and SNRIs typically take 6-12 weeks to become clinically significant, highlighting the need for patience and adherence to treatment 5
Abrupt discontinuation, especially of shorter-acting SSRIs, can lead to withdrawal symptoms, emphasizing the importance of gradual tapering when discontinuing treatment 7
SSRIs and SNRIs can interact with other medications through CYP450 enzyme pathways, highlighting the need for careful consideration of potential drug interactions when prescribing these medications 7